Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115463) titled 'Real-World Application Demonstration of Recombinant Human Tumor Necrosis Factor Receptor-Fc Fusion Protein Injection in Patients with Inflammatory Arthritis' on Dec. 26, 2025.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Condition:
Inflammatory arthritis, including rheumatoid arthritis and ankylosing spondylitis
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-01-01
Target Sample Size: Recombinant Human Tumor Necrosis Factor Receptor-Fc Fusion Protein Injection Exposure g...